Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Recommendation of “Hold” from Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have been given a consensus recommendation of “Hold” by the nine analysts that are covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.39.

A number of analysts recently issued reports on the company. StockNews.com assumed coverage on Revance Therapeutics in a research report on Tuesday, January 21st. They set a “hold” rating for the company. Mizuho cut their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. HC Wainwright restated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, Barclays reduced their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd.

Revance Therapeutics Price Performance

Shares of RVNC opened at $3.65 on Friday. The company has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.86. The business’s 50-day moving average is $3.42 and its 200-day moving average is $4.58. Revance Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $7.56.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. Equities research analysts expect that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Revance Therapeutics

Institutional investors have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC bought a new stake in Revance Therapeutics during the 2nd quarter valued at approximately $33,000. Hsbc Holdings PLC acquired a new position in shares of Revance Therapeutics during the second quarter worth approximately $38,000. FORA Capital LLC bought a new stake in shares of Revance Therapeutics in the third quarter valued at approximately $54,000. Creative Planning acquired a new stake in shares of Revance Therapeutics in the third quarter worth $56,000. Finally, Sei Investments Co. increased its position in Revance Therapeutics by 52.5% during the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 7,628 shares during the period. 97.70% of the stock is currently owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.